StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies Not Concerned About 'Crown Use' of Vertex's (VRTX) Orkambi
February 1, 2019 8:27 AM
Jefferies analyst Michael Yee reiterated a Buy rating and $210 price target on Vertex (NASDAQ: VRTX) noting that on Feb ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Trader Talk
Next Articles
Vertex Pharma (VRTX) Tops Q4 EPS by 24c, Revenues Beat; Offers FY19 Revenue Guidance
February 5, 2019 4:03 PM